MAbSilico Email Format
Biotechnology ResearchCentre-val De Loire, France11-50 Employees
MAbSilico is a mid-sized biotechnology research company based in Tours, Centre-Val de Loire, France, that develops AI-driven solutions for antibody drug design and discovery. It provides computational antibody candidates in days, designed in silico and validated with advanced biological technologies to help biotech and pharmaceutical firms mitigate discovery risks. The company assesses candidates based on epitopes, affinity, off-target risk, cross-species reactivity, and developability, aiming to prepare them for biological activity evaluation, while gathering target and landscape data from multiple databases to support competitive analyses and freedom-to-operate considerations. In March 2024, MAbSilico announced a collaboration with Rapid Novor to offer an AI-driven HDX-MS epitope mapping service for antibody development. The firm positions itself in the AI-enabled biotechnology discovery space and serves biotech and pharma customers with a small-to-mid-sized team.